| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Dr. Reddy's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹64.00 |
| 52 Week High | ₹70.00 |
| 52 Week Low | ₹52.01 |
| Beta | 0.34 |
| 11 Month Change | 2.17% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 39.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| R1DY34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | 1.7% |
| 1Y | n/a | -27.6% | -0.2% |
Return vs Industry: Insufficient data to determine how R1DY34 performed against the BR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how R1DY34 performed against the BR Market.
Price Volatility
| R1DY34 volatility | |
|---|---|
| R1DY34 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 9.2% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: R1DY34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine R1DY34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 27,048 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Dr. Reddy's Laboratories Limited Fundamentals Summary
| R1DY34 fundamental statistics | |
|---|---|
| Market cap | R$71.08b |
| Earnings (TTM) | R$3.64b |
| Revenue (TTM) | R$18.27b |
19.5x
P/E Ratio3.9x
P/S RatioIs R1DY34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R1DY34 income statement (TTM) | |
|---|---|
| Revenue | ₹279.16b |
| Cost of Revenue | ₹115.56b |
| Gross Profit | ₹163.61b |
| Other Expenses | ₹107.92b |
| Earnings | ₹55.68b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 27, 2024
| Earnings per share (EPS) | 334.36 |
| Gross Margin | 58.61% |
| Net Profit Margin | 19.95% |
| Debt/Equity Ratio | 5.9% |
How did R1DY34 perform over the long term?
See historical performance and comparison